Rich Pharmaceuticals (RCHA) 10-Q 6 Dec 17 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jun. 30, 2017	Dec. 04, 2017
Document And Entity Information
Entity Registrant Name	Rich Pharmaceuticals, Inc.
Entity Central Index Key	1,504,389
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		350,136,570
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,018

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2017	Mar. 31, 2017
Current Assets
Cash and equivalents	$ 3,698	$ 40,903
Prepaid expenses
Notes receivable	15,300	10,000
Total Current Assets	18,998	50,903
Property and equipment, net	1,851	2,125
TOTAL ASSETS	20,849	53,028
Current Liabilities
Accounts payable	350,184	296,635
Accounts payable related party	197,450	53,000
Accrued expenses	1,077,101	937,783
Due to related parties	56,203	49,395
Note payable	920,000	920,000
Convertible notes payable, net of debt discount of $505,253 and $356,819	402,775	514,075
Derivative liabilities	4,526,179	2,607,959
Total Current Liabilities	7,529,892	5,378,847
Long-term Liabilities
Convertible notes payable, net of debt discount
Derivative liabilities
Total Long-term Liabilities
Total Liabilities	7,529,892	5,378,847
Commitments and Contingencies	0	0
Stockholders Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively	6,000	6,000
Common stock, $0.001 par value, 2,000,000,000 shares authorized, 332,735,515 and 101,446,215 shares issued and outstanding,	332,735	101,446
Additional paid-in capital	6,898,875	7,011,504
Accumulated deficit	(14,746,653)	(12,444,769)
Total Stockholders Deficit	(7,509,043)	(5,325,819)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$ 20,849	$ 53,028

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2017	Mar. 31, 2017
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ .001	$ .001
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Issued	332,735,515	101,446,215
Preferred Stock, Par Value	$ .001	$ .001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	6,000,000	6,000,000
Convertible notes payable, debt discount	$ 505,253	$ 356,819

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Consulting expenses	4,625	10,225
Office expenses	66,402	34,574
Depreciation expense	274	431
Wages and taxes	137,789	95,954
Professional fees	64,757	54,243
Regulatory fees	34,309	6,843
Research and development	147,573
Stock-based compensation
Travel, meals and entertainment	15,746	13,205
TOTAL OPERATING EXPENSES	471,475	215,475
LOSS FROM OPERATIONS	(471,475)	(215,475)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(350,330)	(46,573)
Change in value of derivative liability	(1,396,990)	116,771
Derivative expense	(249,457)
Interest expense	(46,773)	(33,009)
Interest expense related party	(153)	(75)
Gain (Loss) on extinguishment of debt	213,294
LOSS BEFORE PROVISION FOR INCOME TAXES	(2,301,884)	(178,361)
PROVISION FOR INCOME TAXES
NET LOSS	$ (2,301,884)	$ (178,361)
NET LOSS PER SHARE: BASIC AND DILUTED	$ (0.01)	$ (0.01)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	190,775,667	16,070,556

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (2,301,884)	$ (178,361)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	274	431	$ 1,606
Amortization of debt discount	350,330	46,573
Change in value of derivative liability	1,396,990	(116,771)
Derivative expense	249,457
Gain on extinguishment of debt	(213,294)
Warrants issued for services
Stock-based compensation
Changes in operating assets and liabilities:
Decrease in prepaid expenses
Increase (decrease) in bank overdraft		(1,006)
Increase in accounts payable	197,999	15,390
Increase in accrued expenses	139,318	97,820
Net Cash Used by Operating Activities	(175,969)	(132,475)
CASH FLOWS FROM INVESTING ACTIVITY:
Increase in notes receivable	(5,300)
Net Cash Used by Investing Activities	(5,300)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties	6,810	(37,775)
Proceeds from sale of common stock and warrants
Proceeds from issuance of note payable
Proceeds from issuance of convertible notes payable	137,254	170,250
Net Cash Provided by Financing Activities	144,064	132,475
Net Increase (Decrease) in Cash and Cash Equivalents	(37,205)
Cash and cash equivalents, beginning of period	40,903
Cash and cash equivalents, end of period	3,698		$ 40,903
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Accounts payable converted into note payable
Warrants issued for accrued expenses
Original issue discounts recorded on notes payable	10,000	11,531
Debt discounts recorded on convertible notes payable	498,764
Debt/interest converted into common stock and contributed capital	$ 118,660	$ 449,825

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. (All shares stated at post-split amounts.) On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At June 30, 2017 and March 31, 2017 the Company had $3,698 and $40,903, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, as filed with the U.S. Securities and Exchange Commission. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at June 30, 2017 or March 31, 2017. As of June 30, 2017, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Research and Development The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. (All shares are stated at post-split amounts). Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Total potential dilutive instruments are 6.8 billion common shares upon conversion of existing convertible debt instruments, 9,446,533 common stock warrants, and 29,195,000 common shares upon exercise of outstanding options. In periods of net losses the dilutive loss per share is the same as the basic loss per share because the effect of the dilutive shares in periods of loss is antidilutive. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment

Property and equipment	3 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment, recorded at cost, consisted of the following as of March 31, 2017 and 2016: June 30, 2017 March 31, 2017 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (3,309 ) (3,035 ) Property and equipment, net $ 1,851 $ 2,125 The useful life of the computer equipment and furniture is 3 years. Depreciation expense was $274 and $1,606 for the periods ended June 30, 2017 and March 31, 2017, respectively.

Intangible Assets

Intangible Assets	3 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consisted of the following as of June 30, 2017 and March 31, 2017: June 30, 2017 March 31, 2017 Wages and taxes $ 933,874 $ 829,231 Accrued interest 143,227 108,552 Total accrued expenses $ 1,077,101 $ 937,783

Related Party Debt and Transact

Related Party Debt and Transactions	3 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Debt and Transactions	During the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended March 31, 2017 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest and has an original due date of January 8, 2016. There is a total due of $12,280 as of June 30, 2017 and March 31, 2017. Interest accrued on the note as of June 30, 2017 was $1,056. The Company is in default on the balance of this note. During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending March 31, 2017 received an additional $14,450, and has repaid $36,300 of these loans leaving a total due of $350 as of June 30, 2017. These loans are deemed to be short-term and are payable at the discretion of the Company. Periodically, related parties incur expenses for the Company and are expected to be repaid for those expenditures. As of June 30, 2017, the balance owed to related parties for these types of expenses is $42,515. These liabilities do not have stated interest rates or due dates, but are payable at the discretion of the Company. The Company has a consulting agreement with a related party to provide research into new technologies as well as essential development of current products. The amounts owed to this related party for past work is a part of accounts payable and totals $197,450 and $53,000 for the periods ending June 30, 2017 and March 31, 2017, respectively. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years, and has been extended for an additional two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 1,500 shares of common stock at an exercise price of $40.00 per share. The CEO earned $68,750 and $275,000 for the three months ended June 30, 2017 and the twelve months ended March 31, 2017 (respectively) as a result of this agreement, these amounts contribute to the $691,778 and $645,945 of officer compensation which is included in accrued expenses, as of June 30, 2017 and March 31, 2017.

Note Payable

Note Payable	3 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Note Payable	On May 31, 2016, the Company issued a secured promissory note in the amount of $900,000. The note is due on August 1, 2017 and bears interest at 10% per annum. The loan replaced an account payable to a legal professional to cover past due amounts and penalties for non-payment. The note is guaranteed personally by two shareholders and collateralized by assets of the company and guarantors. Accrued interest was $100,397 as of June 30, 2017. On February 21, 2017, the Company issued a non-secured promissory note in the amount of $20,000. The note is due on August 21, 2017 and bears interest at 8% per annum. The loan was in payment for professional fees related to an equity financing agreement dated February 21, 2017, thus no cash was received by the Company. Accrued interest was $565 as of June 30, 2017.

Convertible Note Payable

Convertible Note Payable	3 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Convertible Note Payable	On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 619,652 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. On February 22, 2017, this note was purchased for a renegotiated face value of $59,799, incurring additional financing fees of $11,819. (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 2,886,693 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 2,324,229 shares of common stock leaving a remaining balance of $ 8,838. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 796,236 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 906,763 shares of common stock. During the period ending March 31, 2017 the note holder converted $60,439 in principal and $6,839 in accrued interest into 44,551,004 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of . On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of . On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending the note holder converted $15,000 in principal and $939 in accrued interest into 4,351,619 shares of common stock leaving a remaining balance of $0. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016 , The loan becomes convertible on , 2015, the issue date of the note. The loan can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 1,796,394 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period prior to the conversion date. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date.. During the period ending the note holder converted $16,745 in principal and $1,380 in interest into 3,325,000 shares of common stock leaving a remaining balance of $10,755. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or before June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $134,214, incurring additional financing fees of $49,964. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0. On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of June 30, 2017 the accrued interest balance is $4,566. On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or before July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $32,000. The note bears interest at the rate of 8% and must be repaid on or before October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On November 17, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On January 5, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $335,000. The note bears interest at the rate of 10%, contains a $30,000 OID, and must be repaid by October 5, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or January 5, 2017, On February 20, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $563,028 which is partially funded, the current balance consolidates unpaid convertible notes dated March 9, 2015; September 4, 2015; December 29, 2015; February 25, 2016; March 24, 2016; May 25, 2016; June 8, 2016; June 23, 2016; July 7, 2016; October 20, 2016; November 17, 2016. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 20, 2017, On February 21, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $15,000. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 21, 2017, On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $59,799, which refinances an unpaid convertible note dated February 5, 2015. The note bears interest at the rate of 10%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $20,900, which refinances an unpaid convertible note dated May 6, 2015. The note bears interest at the rate of 10%, and must be repaid by October 22, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, On April 4, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $71,457, which refinances an unpaid convertible note dated January 22, 2016. The note bears interest at the rate of 8%, and must be repaid by January 4, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , On April 18, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $115,000. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $5000 to cover transaction costs, the note must be repaid by January 30, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or ,

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Derivative Liabilities	In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending June 30, 2017 and March 31, 2017: $29,680 note dated March 26, 2015; $60,500 note dated January 22, 2016 $56,000 note dated June 23, 2016; $58,000 note dated July 7, 2016; $32,000 note dated October 20, 2016; $56,000 note dated November 17, 2016; $335,000 note dated January 5, 2017; $563,028 note dated February 20, 2017; $15,000 note dated February 21, 2017; $59,799 note dated February 22, 2017; $20,900 note dated February 22, 2017; $71,457 note dated April 4, 2017; $90,000 note dated April 18, 2017. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended June 30, 2017, the Company recorded a total change in the fair market value of the derivative liabilities of $1,360,972. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0007-$0.004, exercise price of $0.0001 - $0.001, dividend yield of zero, years to maturity of 0.01918 – .5863, a risk free rate of 0.77% - 1.14%, and annualized volatility of 248% - 1087%. The above loans were all discounted in full. Based on the valuations on the initial valuation dates for the period ending June 30, 2017, the Company recognized debt discounts related to the conversion features totaling $350,330 and a derivative expense of $249,457 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of June 30, 2017, unamortized debt discount, including original issue discounts totaled $505,253. The derivative liabilities totaled $4,526,179 as of June 30, 2017, of which $- related to long-term debt.

Equity Transactions

Equity Transactions	3 Months Ended
	Jun. 30, 2017
Equity Transactions
Equity Transactions	The Company has 2,000,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date March 30, 2017 Warrants 9,200,000 Stock price on grant date $ 0.002 Exercise price $ 0.002 Expected life 5 year Volatility 120 % Risk-free rate 1.96 % Calculated value $ 15,278 Fair value allocation of proceeds $ 45,466 The following is a summary of the warrant activity for the period March 31, 2017 to June 30, 2017: Number of warrants Weighted average exercise price Outstanding, March 31, 2017 9,446,533 $0.102 Granted - - Exercised - - Outstanding, June 30, 2017 9,446,533 $0.102 Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. During the period ended June 30, 2017, the Company issued common stock to satisfy convertible debt conversions at a price below par value as obligated by contract. During this period the company issued 779,232,358 common shares at a below par rate, incurring an adjustment to additional paid in capital of $502,027. During the period ended March 31, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002 During the period ended June 30, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share April 5, 2017 $6,233 5,300,000 $0.00118 April 10, 2017 $6,586 5,600,000 $0.00118 April 11, 2017 $6,880 5,850,000 $0.00118 April 18, 2017 $7,291 6,200,000 $0.00118 April 20, 2017 $7,644 6,500,000 $0.00118 April 21, 2017 $16,464 14,000,000 $0.00118 April 25, 2017 $17,287 14,700,000 $0.00118 April 26, 2017 $26,600 26,600,000 $0.00100 May 1, 2017 $8,700 14,500,000 $0.00060 June 13, 2017 $1,200 10,000,000 $0.00012 June 16, 2017 $1,930 19,299,400 $0.00010 June 16, 2017 $1,300 11,000,000 $0.00012 June 20, 2017 $1,392 11,600,000 $0.00012 June 21, 2017 $2,314 23,139,900 $0.00010 June 22, 2017 $1,590 13,250,000 $0.00012 June 22, 2017 $1,470 12,250,000 $0.00012 June 26, 2017 $1,800 15,000,000 $0.00012 June 29, 2017 $1,980 16,500,000 $0.00012 June 30, 2017 Total $118,660 231,289,300 (2) Effective April 6, 2015, the Company approved the re-pricing of all 135,627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $3.40 per share, to $1.60 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 185.627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $0.40 per share, to $0.40 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date April 6, 2015 June 9, 2015 December 15, 2015 March 30, 2017 Options 102,000 50,000 43,000 29,000,000 Stock price grant date $1.60 $0.40 $0.20 $0.002 Initial Exercise price $1.60 $0.40 $0.20 $0.002 Modified Exercise price $0.20 $0.20 $0.20 - Expected life 5.0 5.0 5.0 5.0 Volatility 99% 99% 84% 120% Risk-free rate 1.31% 1.74% 1.70% 1.93% Calculated value $120,778 $14,838 $5,736 $48,017 Modified value $151,221 $16,347 $5,736 $48,017 The following is a summary of the option activity for the period March 31, 2017 through June 30, 2017: Number of options Weighted average exercise price Outstanding, March 31, 2017 29,228,627 $0.004 Granted - - Exercised - - Expired - - Outstanding, June 30, 2017 29,228,627 $0.004 The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined.

Commitments and Contigencies

Commitments and Contigencies	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Commitments and Contingencies	The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,800. On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation. On April 1, 2017, the Company entered into a tentative agreement with CannCodex to purchase their data base assets in return for issuing 78,000,000 shares of the Company’s common stock. However, this agreement was not finalized and subsequently the Company is not responsible for issuance of the stock. Unrelated to this agreement, the Company has issued short-term loans to CannCodex totaling $15,300 as of June 30, 2017.

Liquidity and Going Concern

Liquidity and Going Concern	3 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern for the twelve months following the date that these financial statements were issued. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

Subsequent Events

Subsequent Events	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Subsequent Events	On July 7, 2017, the Company entered into a two year consulting agreement with a related party. The agreement stipulates payment for scientific, clinical and regulatory services to the related party of $180,000 per year ($15,000 per month) with the option of common stock payment in lieu of cash. On July 11, 2017, Rich Pharmaceuticals , Inc. (the “Company”) entered into a Support and Collaboration Agreement (the “Collaboration Agreement”) with Mega Bridge, Inc., a Nevada corporation to be renamed “Hypgen”) (“Hypgen”), to support Hypgen’s development of treatments for Parkinson’s Disease. Under the terms of the agreement, the Company will provide data, raw materials and advisory support to Hypgen to assist Hypgen with their development of treatments for Parkinson’s Disease and the associated regulatory approval process. In exchange, Hypgen will pay the Company $100,000 and issue the Company 15,000,000 shares of Hypgen common stock. The Company plans to dividend five million of these shares to its shareholders at such time as the Company completes the necessary corporate and regulatory requirements regarding payment of a dividend. Relating to the quarters ended June 30, 2017 and September 30, 0217, an “Event of Default” has occurred under the terms of each of the Company’s previously disclosed convertible promissory notes issued to GHS Investments LLC because the Company has not remained current in its timely filings of its Form 10Q for the period ending June 30, 2017 and September 30, 2017 with the Securities and Exchange Commission. These Events of Default have resulted in $65,958 of penalties which is being recognized during the quarter ended September 30, 2017. Subsequent to the period ended June 30, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share July 3, 2017 $2,088 17,400,000 $0.00012 July 12, 2017 $2,088 17,400,000 $0.00012 July 13, 2017 $2,484 13,800,000 $0.00018 July 14, 2017 $3,374 19,000,000 $0.00018 July 18, 2017 $3,374 19,000,000 $0.00018 July 20, 2017 $3,582 19,900,000 $0.00018 July 24, 2017 $6,270 20,900,000 $0.0003 July 25, 2017 $6,870 22,900,000 $0.0003 July 28, 2017 $7,200 24,000,000 $0.0003 August 2, 2017 $7,200 24,000,000 $0.0003 August 4, 2017 $9,000 25,000,000 $0.00036 August 8, 2017 $11,119 26,475,000 $0.00042 August 11, 2017 $13,920 29,000,000 $0.00048 August 16, 2017 $12,810 30,500,000 $0.00042 August 22, 2017 $6,709 19,168,058 $0.00035 August 25, 2017 $11,200 32,000,000 $0.00035 August 31, 2017 $9,600 32,000,000 $0.0003 September 7, 2017 $9,900 36,000,000 $0.00028 September 15, 2017 $9,437 37,900,000 $0.00025 September 22, 2017 $9,910 39,800,000 $0.00025 September 28, 2017 $10,408 41,800,000 $0.00025 October 3, 2017 $10,931 43,900,000 $0.00025 October 5, 2017 $7,582 30,448,193 $0.00025 Subsequent Total $177,056 622,291,251 In accordance with ASC 855-10, the Company has analyzed its operations subsequent to June 30, 2017 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Nature of Business	On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. (All shares stated at post-split amounts.) On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.
Cash and Cash Equivalents	The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At June 30, 2017 and March 31, 2017 the Company had $3,698 and $40,903, respectively, of unrestricted cash.
Basis of Presentation	The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, as filed with the U.S. Securities and Exchange Commission.
Property and Equipment	Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.
Long-Lived and Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at June 30, 2017 or March 31, 2017. As of June 30, 2017, the derivative liabilities were considered a level 2 item; see Note 8.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Income Taxes	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Revenue Recognition	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.
Research and Development	The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.
Stock-Based Compensation	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. (All shares are stated at post-split amounts).
Basic loss per share	The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Total potential dilutive instruments are 6.8 billion common shares upon conversion of existing convertible debt instruments, 9,446,533 common stock warrants, and 29,195,000 common shares upon exercise of outstanding options. In periods of net losses the dilutive loss per share is the same as the basic loss per share because the effect of the dilutive shares in periods of loss is antidilutive.
Recent Accounting Pronouncements	The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment (Tables)

Property and equipment (Tables)	3 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	June 30, 2017 March 31, 2017 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (3,309 ) (3,035 ) Property and equipment, net $ 1,851 $ 2,125

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	June 30, 2017 March 31, 2017 Wages and taxes $ 933,874 $ 829,231 Accrued interest 143,227 108,552 Total accrued expenses $ 1,077,101 $ 937,783

Equity Transactions (Tables)

Equity Transactions (Tables)	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Schedule of Value of Warrants	Date June 9, 2015 Dec 15,2015 March 30, 2017 Warrants 45,000 200,000 9,200,000 Stock price on grant date $0.40 $0.20 $0.002 Exercise price $0.40 $0.20 $0.002 Expected life 5 year 5 year 5 year Volatility 98% 98% 120% Risk-free rate 1.74% 1.71% 1.96% Calculated value $13,259 $29,612 $15,278 Fair value allocation of proceeds $13,259 $29,612 $45,466
Schedule of Warrant Activity	Number of warrants Weighted average exercise price Outstanding, March 31, 2016 246,533 $3.84 Granted 9,200,000 $0.002 Exercised - - Outstanding, March 31, 2017 9,446,556 $0.102
Schedule of Conversions of Common Stock	Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 20,556 $0.81000 April 6, 2015 $10,000 10,482 $0.95400 April 8, 2015 $15,309 22,678 $0.67500 April 8, 2015 $20,001 22,727 $0.88000 April 9, 2015 $14,320 16,273 $0.88000 April 14, 2015 $10,000 11,848 $0.84400 April 16, 2015 $1,918 2,650 $0.72380 April 21, 2015 $10,000 12,987 $0.77000 April 29, 2015 $15,000 19,481 $0.77000 May 4, 2015 $5,083 6,573 $0.77320 May 12, 2015 $28,456 45,169 $0.63000 May 20, 2015 $20,199 47,382 $0.42620 May 20, 015 $17,240 39,182 $0.44000 May 27, 2015 $13,568 35,090 $0.38660 May 29, 2015 $15,000 44,118 $0.34000 June 11, 2015 $9,897 47,130 $0.21000 June 16, 2015 $14,100 58,750 $0.24000 June 16, 2015 $13,565 56,521 $0.24000 June 22, 2015 $7,415 61,792 $0.12000 June 22, 2015 $14,384 123,996 $0.11600 June 23, 2015 $7,752 64,600 $0.12000 September 16, 2015 $7,974 88,602 $0.09000 September 28, 2015 $10,000 83,333 $0.12000 September 29, 2015 $10,620 88,500 $0.12000 October 7, 2015 $2,250 18,750 $0.12000 October 7, 2015 $8,400 70,000 $0.12000 October 19, 2015 $9,720 81,000 $0.12000 November 2, 2015 $4,424 98,306 $0.04500 November 23, 2015 $10,000 83,333 $0.12000 November 30, 2015 $16,844 129,566 $0.13000 December 9, 2015 $1,746 38,800 $0.04500 December 17, 2015 $5,332 45,966 $0.11600 December 28, 2015 $1,341 29,810 $0.04500 December 28, 2015 $17,700 147,500 $0.12000 December 28, 2015 $14,305 119,208 $0.12000 December 28, 2015 $14,963 128,996 $0.11600 December 29, 2015 $8,395 69,958 $0.12000 December 29, 2015 $7,670 63,917 $0.12000 December 30, 2015 $6,651 147,812 $0.04500 January 1, 2016 $28,500 219,231 $0.13000 January 4, 2016 $19,339 161,161 $0.12000 January 5, 2016 $8,107 180,161 $0.04500 January 6, 2016 $16,070 133,917 $0.12000 January 6, 2016 $16,597 143,080 $0.11600 February 16 ,2016 $1,424 211,020 $0.00680 February 17, 2016 $12,800 422,164 $0.03040 February 23, 2016 $4,640 210,909 $0.02200 February 23, 2016 $3,086 210,044 $0.01460 February 24, 2016 $1,492 220,999 $0.00680 February 25, 2016 $3,000 131,949 $0.02280 February 25, 2016 $4,640 210,909 $0.02200 March 1, 2016 $1,313 291,723 $0.00440 March 2, 2016 $4,600 291,582 $0.01580 March 2, 2016 $1,650 129,321 $0.01280 March 2, 2016 $9,332 582,500 $0.01600 March 7, 2016 $2,799 327,315 $0.00860 March 11, 2016 $1,924 207,375 $0.00920 March 14, 2016 $2,245 356,289 $0.00640 March 15, 2016 $3,329 372,705 $0.00900 March 15, 2016 $5,210 572,500 $0.00920 March 22, 2016 $2,419 447,894 $0.00540 March 22, 2016 $2,367 360,023 $0.00660 March 22, 2016 $5,315 584,100 $0.00920 March 28, 2016 $1,986 447,939 $0.00440 March 31, 2016 Total $602,376 9,730,152 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002
Schedule of Value of Options	Date April 6, 2015 June 9, 2015 December 15, 2015 March 30, 2017 Options 102,000 50,000 43,000 29,000,000 Stock price grant date $1.60 $0.40 $0.20 $0.002 Initial Exercise price $1.60 $0.40 $0.20 $0.002 Modified Exercise price $0.20 $0.20 $0.20 - Expected life 5.0 5.0 5.0 5.0 Volatility 99% 99% 84% 120% Risk-free rate 1.31% 1.74% 1.70% 1.93% Calculated value $120,778 $14,838 $5,736 $48,017 Modified value $151,221 $16,347 $5,736 $48,017
Schedule of Option Activity	Number of options Weighted average exercise price Outstanding, March 31, 2016 228,627 $0.20 Granted 29,000,000 $0.002 Exercised - - Expired - - Outstanding, March 31, 2017 29,228,627 $0.004

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended	12 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016shares	Mar. 31, 2013$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Date Of Incorporation	Aug. 9, 2010
Cancellation of loans | $
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000		375,030,000	375,030,000	900,000
Common Stock, Par Value | $ / shares	$ .001	$ .001		$ 0.001	$ 0.001	$ 0.001
Stock split ratio	0.05		0.01	4.1671
Cash and cash equivalent | $	$ 3,698	$ 40,903
Reserved common shares					195,002
Computer equipment	3 years
Options granted, number of shares		29,000,000	195,000
Dilutive Instruments, common stock warrants	9,446,533
Dilutive Instruments, common stock shares	29,195,000
Sale Agmt
Date of Agreement	Jul. 19, 2013
Cancellation of loans | $	$ 28,818
Shares sold by former officers	265,646
Shares returned to treasury	250,128
Shares agreed to cancel	131,261
Asset Assign Agmt
Date of Agreement	Jul. 18, 2013
Common Stock, shares issued	41,384
Series A Preferred Stock, shares issued	6,000,000
Stock Value | $	$ 123,973
Termination of agreement | $	20,000
Additional cash required | $	$ 2,000,000

Property and equipment - Schedu

Property and equipment - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2017	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Computer equipment	$ 5,160	$ 5,160
Less: accumulated depreciation	(3,309)	(3,035)
Property and equipment, net	$ 1,851	$ 2,125

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017
Property And Equipment Details Narrative
Depreciation expense	$ 274	$ 431	$ 1,606
Computer equipment	3 years

Intangible Assets (Details Narr

Intangible Assets (Details Narrative)	3 Months Ended
	Jun. 30, 2017USD ($)shares
Asset Assign Agmt
Date of Agreement	Jul. 18, 2013
Common Stock, shares issued | shares	41,384
Series A Preferred Stock, shares issued | shares	6,000,000
Stock Value	$ 123,973
Impaired Assets	0
Asset Development Cost	$ 45,000
Asset Assign Agmt #2
Date of Agreement	Oct. 6, 2014
Common Stock, shares issued | shares	110,396
Common stock, value	$ 7,904,355
Impaired Assets	0
Impairment of intangible asset	$ 82,120

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jun. 30, 2017	Mar. 31, 2017
Payables and Accruals [Abstract]
Wages and taxes	$ 933,874	$ 829,231
Accrued interest	143,227	108,552
Total accrued expenses	$ 1,077,101	$ 937,783

Related Party Debt and Transa27

Related Party Debt and Transactions (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Mar. 31, 2015	Mar. 31, 2016
Cancellation of loans
Due to related parties	56,203		$ 49,395
Loans and interest received (repaid) from/to related parties	6,810	$ (37,775)
Interest expense, related party	(153)	$ (75)
Accrued expenses	1,077,101		937,783
Accounts payable related party	197,450		53,000
SH Loan #1
Due Date				Jan. 8, 2016
Loan from related party				$ 6,000
Interest Rate				8.00%
SH Loan #2
Loan from related party	6,280
Due to related parties	$ 12,280
Interest Rate	8.00%
Interest expense, related party	$ 1,056
Related Party Loans
Due to related parties	350
Repayment of loans to related parties	42,515
Loans and interest received (repaid) from/to related parties	$ 36,300
Accrued expenses			14,450		$ 22,200
Employment Agmt
Date of Agreement	Sep. 6, 2013
Term of Agreement	2 years
Annual Compensation	$ 275,000
Options to purchase	1,500
Options to purchase, exercise price	$ 40
Bonus	$ 68,750
Earnings	275,000		275,000
Accrued Earnings	$ 691,778		$ 645,945

Note Payable (Details Narrative

Note Payable (Details Narrative)	3 Months Ended
	Jun. 30, 2017USD ($)
Note Payable #1
Date of Agreement	May 31, 2016
Convertible Note	$ 900,000
Interest Rate	10.00%
Due Date	Aug. 1, 2017
Interest Accrued	$ 100,397
Note Payable #2
Date of Agreement	Feb. 21, 2017
Convertible Note	$ 20,000
Interest Rate	8.00%
Due Date	Aug. 21, 2017
Interest Accrued	$ 565

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)	3 Months Ended			12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument, Converted Amount	$ 118,660		$ 449,825
Convertible Prom Note #15
Date of Agreement					Feb. 5, 2015
Convertible Note					$ 54,000
Interest Rate					8.00%
Due Date					Nov. 9, 2015
Interest Accrued	0
Convertible Note, Balance	0			$ 59,799	$ 47,980
Debt Instrument, Converted Amount					$ 33,020
Common Stock, shares issued					619,652
Fee				Financing	Default
Fee Amount		$ 11,819		$ 11,819	$ 27,000
Convertible Prom Note #18
Date of Agreement					Mar. 9, 2015
Convertible Note					$ 55,000
Interest Rate					8.00%
Due Date					Jun. 23, 2017
Interest Accrued			0	0	$ 0
Convertible Note, Balance			8,838	0	16,215
Debt Instrument, Converted Amount			7,377		38,785
Debt Instrument, Interest Accrued, Converted Amount			$ 422		$ 5,135
Common Stock, shares issued			2,324,229		2,886,693
Convertible Prom Note #19
Date of Agreement			Mar. 26, 2015
Convertible Note			$ 29,680
Interest Rate			8.00%
Due Date			Mar. 23, 2016
Interest Accrued	7,418		$ 2,577
Convertible Note, Balance			18,751
Original Issue Discount			1,680
Debt Instrument, Converted Amount			$ 10,929
Common Stock, shares issued			796,236
Convertible Prom Note #21
Date of Agreement			May 5, 2015
Convertible Note			$ 68,900
Interest Rate			8.00%
Due Date			May 5, 2016
Interest Accrued				0
Convertible Note, Balance				0
Original Issue Discount			$ 3,900
Debt Instrument, Converted Amount			8,461	60,439
Debt Instrument, Interest Accrued, Converted Amount			$ 566	$ 6,839
Common Stock, shares issued			906,763	44,551,004
Convertible Prom Note #22
Date of Agreement				May 6, 2015
Convertible Note				$ 10,500
Interest Rate				8.00%
Due Date				Feb. 8, 2016
Interest Accrued	0
Convertible Note, Balance	0	$ 20,900		$ 15,750
Fee		Financing		Default
Fee Amount	$ 5,150	$ 5,250		$ 5,250
Convertible Prom Note #24
Date of Agreement				Aug. 28, 2015
Convertible Note				$ 15,000
Interest Rate				8.00%
Due Date				Aug. 28, 2016
Interest Accrued				$ 0
Convertible Note, Balance				0
Debt Instrument, Converted Amount				15,000
Debt Instrument, Interest Accrued, Converted Amount				$ 939
Common Stock, shares issued				4,351,619
Convertible Prom Note #25
Date of Agreement				Sep. 4, 2015
Convertible Note				$ 19,000
Interest Rate				8.00%
Due Date				Jun. 4, 2016
Interest Accrued		0
Convertible Note, Balance		0		$ 20,280
Fee				Financing
Fee Amount		1,280		$ 1,280
Convertible Prom Note #26
Date of Agreement					Dec. 29, 2015
Convertible Note					$ 57,378
Interest Rate					8.00%
Due Date					Jun. 23, 2017
Interest Accrued				0	$ 0
Convertible Note, Balance				$ 0	1,609
Debt Instrument, Converted Amount					59,934
Debt Instrument, Interest Accrued, Converted Amount					$ 1,222
Common Stock, shares issued					1,796,394
Fee					Default
Fee Amount					$ 4,165
Convertible Prom Note #27
Date of Agreement	Jan. 22, 2016
Convertible Note	$ 60,500
Interest Rate	10.00%
Due Date	Oct. 22, 2016
Interest Accrued	$ 0
Convertible Note, Balance	$ 0
Convertible Prom Note #28
Date of Agreement				Feb. 25, 2016
Convertible Note				$ 27,500
Interest Rate				8.00%
Due Date				Feb. 25, 2017
Interest Accrued				$ 0
Convertible Note, Balance				0
Original Issue Discount, unamortized				212
Debt Instrument, Converted Amount				16,745
Debt Instrument, Interest Accrued, Converted Amount				$ 1,380
Common Stock, shares issued				3,325,000
Convertible Prom Note #29
Date of Agreement	Mar. 24, 2016
Convertible Note	$ 7,500
Interest Rate	8.00%
Due Date	Mar. 24, 2017
Interest Accrued	$ 0
Convertible Prom Note #34
Date of Agreement				May 25, 2016
Convertible Note				$ 30,000
Interest Rate				8.00%
Due Date				May 25, 2017
Interest Accrued				$ 0
Convertible Note, Balance				$ 0
Fee				Financing
Fee Amount		8,107		$ 8,107
Convertible Prom Note #30
Date of Agreement				Jun. 8, 2016
Convertible Note				$ 84,250
Interest Rate				8.00%
Due Date				Jun. 8, 2017
Interest Accrued				$ 0
Convertible Note, Balance				$ 0
Fee				Financing
Fee Amount		$ 49,964		$ 49,964
Convertible Prom Note #32
Date of Agreement	Jun. 23, 2016
Convertible Note	$ 56,000
Interest Rate	8.00%
Due Date	Jun. 23, 2017
Interest Accrued	$ 4,566
Convertible Prom Note #35
Date of Agreement	Jul. 7, 2016
Convertible Note	$ 58,000
Interest Rate	8.00%
Due Date	Jul. 7, 2017
Interest Accrued	$ 2,283
Convertible Note, Balance	29,055
Debt Instrument, Converted Amount	28,945
Debt Instrument, Interest Accrued, Converted Amount	$ 1,902
Common Stock, shares issued	69,039,300
Convertible Prom Note #36
Date of Agreement	Oct. 20, 2016
Convertible Note	$ 32,000
Interest Rate	8.00%
Due Date	Oct. 20, 2017
Interest Accrued	$ 1,774
Convertible Prom Note #37
Date of Agreement	Nov. 17, 2016
Convertible Note	$ 56,000
Interest Rate	8.00%
Due Date	Jun. 23, 2017
Interest Accrued	$ 4,566
Convertible Prom Note #38
Date of Agreement	Jan. 5, 2017
Convertible Note	$ 335,000
Interest Rate	10.00%
Due Date	Oct. 5, 2017
Interest Accrued	$ 14,866
Convertible Note, Balance	10,002
Original Issue Discount	$ 30,000
Convertible Prom Note #39
Date of Agreement				Feb. 20, 2017
Convertible Note				$ 563,028
Interest Rate				8.00%
Due Date				Oct. 25, 2017
Interest Accrued				$ 904
Convertible Note, Balance				124,066
Debt Instrument, Converted Amount				84,877
Debt Instrument, Interest Accrued, Converted Amount				$ 2,939
Common Stock, shares issued				162,250,000
Convertible Prom Note #40
Date of Agreement	Feb. 21, 2017
Convertible Note	$ 15,000
Interest Rate	8.00%
Due Date	Oct. 25, 2017
Interest Accrued	$ 424
Convertible Prom Note #41
Date of Agreement	Feb. 22, 2017
Convertible Note	$ 59,799
Interest Rate	10.00%
Due Date	Oct. 25, 2017
Interest Accrued	$ 2,097
Convertible Prom Note #42
Date of Agreement	Feb. 22, 2017
Convertible Note	$ 20,900
Interest Rate	10.00%
Due Date	Oct. 22, 2017
Interest Accrued	$ 733
Convertible Prom Note #43
Date of Agreement	Apr. 4, 2017
Convertible Note	$ 71,457
Interest Rate	8.00%
Due Date	Jan. 8, 2018
Interest Accrued	$ 1,363
Convertible Prom Note #44
Date of Agreement	Apr. 18, 2017
Convertible Note	$ 115,000
Interest Rate	10.00%
Due Date	Jan. 30, 2018
Interest Accrued	$ 1,271
Original Issue Discount	11,500
Original Issue Discount, unamortized	$ 7,222

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017
Notes to Financial Statements
Change in value of derivative liability	$ 1,396,990	$ (116,771)
Derivative expense	(249,457)
Debt Discounts, Conversion Features	350,330
Debt Discount, Unamortized	505,253
Derivative liabilities	4,526,179		$ 2,607,959
Derivative liabilities

Equity Transactions - Schedule

Equity Transactions - Schedule of Value of Warrants (Details) - USD ($)	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Fair value allocation of proceeds
Warrant #10
Date	Mar. 30, 2017
Warrants	$ 9,200,000
Stock price on grant date	$ 0.002
Exercise price	$ 0.002
Expected life	5 years
Volatility	120.00%
Risk-free rate	1.96%
Calculated value	$ 15,278
Fair value allocation of proceeds	$ 45,466

Equity Transactions - Schedul32

Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017
Accounting Policies [Abstract]
Beginning Balance, Issued Warrants	9,446,533
Beginning Balance, Average Exercise Price	$ 0.102
Exercised, Warrants
Exercised, Average Exercise Price
Expired Warrants
Expired Average Exercise Price
Ending Balance, Issued Warrants	9,446,533	9,446,533
Ending Balance, Average Exercise Price	$ 0.102	$ 0.102

Equity Transactions - Schedul33

Equity Transactions - Schedule of Value of Options (Details)	3 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Stock Option 7
Date of Issuance	Apr. 6, 2015
Options | shares	102,000
Stock price on grant date	$ 1.60
Exercise price	1.60
Exercise price, modified	$ 0.20
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.31%
Calculated value | $	$ 120,778
Modified value | $	$ 151,221
Stock Option 8
Date of Issuance	Jun. 9, 2015
Options | shares	50,000
Stock price on grant date	$ 0.40
Exercise price	0.40
Exercise price, modified	$ 0.20
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.74%
Calculated value | $	$ 14,838
Modified value | $	$ 16,347
Stock Option 9
Date of Issuance	Dec. 15, 2015
Options | shares	43,000
Stock price on grant date	$ 0.20
Exercise price	0.20
Exercise price, modified	$ 0.20
Expected life	5 years
Volatility	84.00%
Risk-free rate	1.70%
Calculated value | $	$ 5,736
Modified value | $	$ 5,736
Stock Option 10
Date of Issuance	Mar. 30, 2017
Options | shares	29,000,000
Stock price on grant date	$ 0.002
Exercise price	$ 0.002
Expected life	5 years
Volatility	120.00%
Risk-free rate	1.93%
Calculated value | $	$ 48,017
Modified value | $	$ 48,017

Equity Transactions - Schedul34

Equity Transactions - Schedule of Option Activity (Details) - shares	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Mar. 31, 2016
Accounting Policies [Abstract]
Beginning Balance, number of shares	29,228,627
Beginning Balance, weighted average exercise price	0.004
Options granted, number of shares		29,000,000	195,000
Options exercised, number of shares
Options exercised, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Ending Balance, number of shares	29,228,627	29,228,627
Ending Balance, weighted average exercise price	0.004	0.004

Equity Transactions (Details Na

Equity Transactions (Details Narrative)	3 Months Ended		12 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2016USD ($)	Mar. 31, 2017$ / sharesshares	Mar. 31, 2016shares	Mar. 31, 2013$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares	Jul. 18, 2013shares
Common Stock, Shares Authorized	2,000,000,000		2,000,000,000		375,030,000	375,030,000	900,000
Common Stock, Par Value | $ / shares	$ .001		$ .001		$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000		10,000,000
Preferred Stock, Par Value | $ / shares	$ .001		$ .001
Series A Preferred Stock, Designated								6,000,000
Common Stock, Issued	332,735,515		101,446,215
Preferred Stock, Issued	6,000,000		6,000,000
Stock split ratio	0.05			0.01	4.1671
Options granted, number of shares			29,000,000	195,000
Debt Instrument, Converted Amount | $	$ 118,660	$ 449,825
Stock-based compensation | $
Common Stock Issued, Convertible Debt, Shares	779,232,358
Adjustment to APIC | $	$ 502,027
2013 Stock Option Plan Amendment
Stock-based compensation | $	$ 50,448
2013 Stock Option Plan Amdt #2
Date of Agreement	Apr. 6, 2015
Options granted, number of shares	135,627
Exercise price | $ / shares	$ 1.60
Stock-based compensation | $	$ 9,316
2013 Stock Option Plan Amdt #3
Date of Agreement	Aug. 4, 2015
Options granted, number of shares	185,627
Exercise price | $ / shares	$ 0.40
Stock-based compensation | $	$ 47,463
Debt Conversion #65
Date of Issuance	Jan. 4, 2016
Common Stock, shares issued	161,161
Common Stock, price per share | $ / shares	$ .12000
Debt Instrument, Converted Amount | $	$ 19,339
Debt Conversion #89
Date of Issuance	Apr. 1, 2016
Common Stock, shares issued	488,316
Common Stock, price per share | $ / shares	$ .00450
Debt Instrument, Converted Amount | $	$ 2,197
Debt Conversion #90
Date of Issuance	Apr. 4, 2016
Common Stock, shares issued	862,500
Common Stock, price per share | $ / shares	$ .00562
Debt Instrument, Converted Amount | $	$ 4,847
Debt Conversion #91
Date of Issuance	Apr. 7, 2016
Common Stock, shares issued	486,111
Common Stock, price per share | $ / shares	$ .00360
Debt Instrument, Converted Amount | $	$ 1,750
Debt Conversion #92
Date of Issuance	Apr. 14, 2016
Common Stock, shares issued	962,500
Common Stock, price per share | $ / shares	$ .00432
Debt Instrument, Converted Amount | $	$ 4,158
Debt Conversion #93
Date of Issuance	Apr. 15, 2016
Common Stock, shares issued	488,311
Common Stock, price per share | $ / shares	$ .00270
Debt Instrument, Converted Amount | $	$ 1,318
Debt Conversion #94
Date of Issuance	Apr. 26, 2016
Common Stock, shares issued	631,489
Common Stock, price per share | $ / shares	$ .00270
Debt Instrument, Converted Amount | $	$ 1,705
Debt Conversion #95
Date of Issuance	May 4, 2016
Common Stock, shares issued	485,901
Common Stock, price per share | $ / shares	$ .00426
Debt Instrument, Converted Amount | $	$ 2,067
Debt Conversion #96
Date of Issuance	May 31, 2016
Common Stock, shares issued	230,003
Common Stock, price per share | $ / shares	$ .00360
Debt Instrument, Converted Amount | $	$ 828
Debt Conversion #97
Date of Issuance	Jun. 2, 2016
Common Stock, shares issued	1,500,000
Common Stock, price per share | $ / shares	$ .00608
Debt Instrument, Converted Amount | $	$ 9,120
Debt Conversion #98
Date of Issuance	Jun. 2, 2016
Common Stock, shares issued	1,467,017
Common Stock, price per share | $ / shares	$ .00300
Debt Instrument, Converted Amount | $	$ 4,401
Debt Conversion #99
Date of Issuance	Jun. 14, 2016
Common Stock, shares issued	1,461,795
Common Stock, price per share | $ / shares	$ .00400
Debt Instrument, Converted Amount | $	$ 5,847
Debt Conversion #100
Date of Issuance	Jun. 17, 2016
Common Stock, shares issued	1,422,808
Common Stock, price per share | $ / shares	$ .00400
Debt Instrument, Converted Amount | $	$ 5,691
Debt Conversion #101
Date of Issuance	Jun. 29, 2017
Common Stock, shares issued	1,063,518
Common Stock, price per share | $ / shares	$ .00618
Debt Instrument, Converted Amount | $	$ 6,580
Debt Conversion #102
Date of Issuance	Aug. 23, 2016
Common Stock, shares issued	1,106,487
Common Stock, price per share | $ / shares	$ .00232
Debt Instrument, Converted Amount | $	$ 2,567
Debt Conversion #103
Date of Issuance	Aug. 29, 2016
Common Stock, shares issued	1,107,806
Common Stock, price per share | $ / shares	$ .00232
Debt Instrument, Converted Amount | $	$ 2,570
Debt Conversion #104
Date of Issuance	Sep. 6, 2016
Common Stock, shares issued	1,097,634
Common Stock, price per share | $ / shares	$ .00232
Debt Instrument, Converted Amount | $	$ 2,547
Debt Conversion #105
Date of Issuance	Sep. 20, 2016
Common Stock, shares issued	1,263,383
Common Stock, price per share | $ / shares	$ .00194
Debt Instrument, Converted Amount | $	$ 2,443
Debt Conversion #106
Date of Issuance	Sep. 26, 2016
Common Stock, shares issued	1,269,672
Common Stock, price per share | $ / shares	$ .00232
Debt Instrument, Converted Amount | $	$ 2,946
Debt Conversion #107
Date of Issuance	Sep. 28, 2016
Common Stock, shares issued	1,270,172
Common Stock, price per share | $ / shares	$ .00232
Debt Instrument, Converted Amount | $	$ 2,947
Debt Conversion #108
Date of Issuance	Sep. 30, 2016
Common Stock, shares issued	2,553,336
Common Stock, price per share | $ / shares	$ .00154
Debt Instrument, Converted Amount | $	$ 3,949
Debt Conversion #109
Date of Issuance	Oct. 7, 2016
Common Stock, shares issued	2,914,578
Common Stock, price per share | $ / shares	$ .00116
Debt Instrument, Converted Amount | $	$ 3,381
Debt Conversion #110
Date of Issuance	Oct. 14, 2016
Common Stock, shares issued	2,913,784
Common Stock, price per share | $ / shares	$ .00116
Debt Instrument, Converted Amount | $	$ 3,380
Debt Conversion #111
Date of Issuance	Oct. 21, 2016
Common Stock, shares issued	2,917,784
Common Stock, price per share | $ / shares	$ .00116
Debt Instrument, Converted Amount | $	$ 3,385
Debt Conversion #112
Date of Issuance	Oct. 26, 2016
Common Stock, shares issued	2,915,828
Common Stock, price per share | $ / shares	$ .00116
Debt Instrument, Converted Amount | $	$ 3,382
Debt Conversion #113
Date of Issuance	Oct. 31, 2016
Common Stock, shares issued	4,341,853
Common Stock, price per share | $ / shares	$ .00116
Debt Instrument, Converted Amount | $	$ 5,037
Debt Conversion #114
Date of Issuance	Nov. 7, 2016
Common Stock, shares issued	4,323,647
Common Stock, price per share | $ / shares	$ .00116
Debt Instrument, Converted Amount | $	$ 5,015
Debt Conversion #115
Date of Issuance	Nov. 22, 2016
Common Stock, shares issued	4,753,009
Common Stock, price per share | $ / shares	$ .00116
Debt Instrument, Converted Amount | $	$ 5,513
Debt Conversion #116
Date of Issuance	Nov. 29, 2016
Common Stock, shares issued	4,754,647
Common Stock, price per share | $ / shares	$ .00116
Debt Instrument, Converted Amount | $	$ 5,515
Debt Conversion #117
Date of Issuance	Dec. 6, 2016
Common Stock, shares issued	3,497,966
Common Stock, price per share | $ / shares	$ .00116
Debt Instrument, Converted Amount | $	$ 4,058
Debt Conversion #118
Date of Issuance	Jan. 10, 2017
Common Stock, shares issued	6,301,150
Common Stock, price per share | $ / shares	$ 0.00100
Debt Instrument, Converted Amount | $	$ 6,301
Debt Conversion #119
Date of Issuance	Feb. 22, 2017
Common Stock, shares issued	3,575,000
Common Stock, price per share | $ / shares	$ 0.00120
Debt Instrument, Converted Amount | $	$ 4,290
Debt Conversion #120
Date of Issuance	Mar. 13, 2017
Common Stock, shares issued	3,400,000
Common Stock, price per share | $ / shares	$ 0.00120
Debt Instrument, Converted Amount | $	$ 4,080
Debt Conversion #121
Date of Issuance	Mar. 21, 2017
Common Stock, shares issued	4,100,000
Common Stock, price per share | $ / shares	$ 0.00120
Debt Instrument, Converted Amount | $	$ 4,920
Debt Conversion #122
Date of Issuance	Mar. 22, 2017
Common Stock, shares issued	4,300,000
Common Stock, price per share | $ / shares	$ 0.00120
Debt Instrument, Converted Amount | $	$ 5,160
Debt Conversion #123
Date of Issuance	Mar. 24, 2017
Common Stock, shares issued	4,550,000
Common Stock, price per share | $ / shares	$ 0.00120
Debt Instrument, Converted Amount | $	$ 5,460
Debt Conversion #124
Date of Issuance	Mar. 30, 2017
Common Stock, shares issued	4,800,000
Common Stock, price per share | $ / shares	$ 0.00118
Debt Instrument, Converted Amount | $	$ 5,645
Debt Conversion #125
Date of Issuance	Mar. 31, 2017
Common Stock, shares issued	5,050,000
Common Stock, price per share | $ / shares	$ 0.00118
Debt Instrument, Converted Amount | $	$ 5,939
Debt Conversion #126
Date of Issuance	Apr. 5, 2017
Common Stock, shares issued	5,300,000
Common Stock, price per share | $ / shares	$ 0.00118
Debt Instrument, Converted Amount | $	$ 6,233
Debt Conversion #127
Date of Issuance	Apr. 10, 2017
Common Stock, shares issued	5,600,000
Common Stock, price per share | $ / shares	$ 0.00118
Debt Instrument, Converted Amount | $	$ 6,586
Debt Conversion #128
Date of Issuance	Apr. 11, 2017
Common Stock, shares issued	5,850,000
Common Stock, price per share | $ / shares	$ 0.00118
Debt Instrument, Converted Amount | $	$ 6,880
Debt Conversion #129
Date of Issuance	Apr. 18, 2017
Common Stock, shares issued	6,200,000
Common Stock, price per share | $ / shares	$ 0.00118
Debt Instrument, Converted Amount | $	$ 7,291
Debt Conversion #130
Date of Issuance	Apr. 20, 2017
Common Stock, shares issued	6,500,000
Common Stock, price per share | $ / shares	$ 0.00118
Debt Instrument, Converted Amount | $	$ 7,644
Debt Conversion #131
Date of Issuance	Apr. 21, 2017
Common Stock, shares issued	14,000,000
Common Stock, price per share | $ / shares	$ 0.00118
Debt Instrument, Converted Amount | $	$ 16,464
Debt Conversion #132
Date of Issuance	Apr. 25, 2017
Common Stock, shares issued	14,700,000
Common Stock, price per share | $ / shares	$ 0.00118
Debt Instrument, Converted Amount | $	$ 17,287
Debt Conversion #133
Date of Issuance	Apr. 26, 2017
Common Stock, shares issued	26,600,000
Common Stock, price per share | $ / shares	$ 0.001
Debt Instrument, Converted Amount | $	$ 26,600
Debt Conversion #134
Date of Issuance	May 1, 2017
Common Stock, shares issued	14,500,000
Common Stock, price per share | $ / shares	$ 0.00060
Debt Instrument, Converted Amount | $	$ 8,700
Debt Conversion #135
Date of Issuance	Jun. 13, 2017
Common Stock, shares issued	10,000,000
Common Stock, price per share | $ / shares	$ 0.00012
Debt Instrument, Converted Amount | $	$ 1,200
Debt Conversion #136
Date of Issuance	Jun. 16, 2017
Common Stock, shares issued	11,000,000
Common Stock, price per share | $ / shares	$ 0.00010
Debt Instrument, Converted Amount | $	$ 1,930
Debt Conversion #137
Date of Issuance	Jun. 16, 2017
Common Stock, shares issued	19,299,400
Common Stock, price per share | $ / shares	$ 0.00012
Debt Instrument, Converted Amount | $	$ 1,300
Debt Conversion #138
Date of Issuance	Jun. 20, 2017
Common Stock, shares issued	11,600,000
Common Stock, price per share | $ / shares	$ 0.00012
Debt Instrument, Converted Amount | $	$ 1,382
Debt Conversion #139
Date of Issuance	Jun. 21, 2017
Common Stock, shares issued	23,139,900
Common Stock, price per share | $ / shares	$ 0.00010
Debt Instrument, Converted Amount | $	$ 2,314
Debt Conversion #140
Date of Issuance	Jun. 22, 2017
Common Stock, shares issued	12,250,000
Common Stock, price per share | $ / shares	$ 0.00012
Debt Instrument, Converted Amount | $	$ 1,590
Debt Conversion #141
Date of Issuance	Jun. 22, 2017
Common Stock, shares issued	13,250,000
Common Stock, price per share | $ / shares	$ 0.00012
Debt Instrument, Converted Amount | $	$ 1,470
Debt Conversion #142
Date of Issuance	Jun. 26, 2017
Common Stock, shares issued	15,000,000
Common Stock, price per share | $ / shares	$ 0.00012
Debt Instrument, Converted Amount | $	$ 1,800
Debt Conversion #143
Date of Issuance	Jun. 29, 2017
Common Stock, shares issued	16,500,000
Common Stock, price per share | $ / shares	$ 0.00012
Debt Instrument, Converted Amount | $	$ 1,980
Warrant #10
Exercise Date	Mar. 30, 2017
Warrants | $	$ 9,200,000
Stock price on grant date | $ / shares	$ 0.002
Exercise price | $ / shares	$ 0.002
Expected life	5 years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	3 Months Ended
	Jun. 30, 2017USD ($)shares
Monthly Rent	$ 2,800
Contract
Date of Agreement	Jul. 8, 2016
Contract Duration	27 months
Contract Committment Value	$ 193,255
CannCodex
Date of Agreement	Apr. 1, 2017
Shares issued for services | shares	78,000,000
Loan payable	$ 15,300

Subsequent Event (Details Narra

Subsequent Event (Details Narrative)	3 Months Ended			12 Months Ended
	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2016USD ($)	Mar. 31, 2016	Mar. 31, 2013$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Debt Instrument, Converted Amount		$ 118,660	$ 449,825
Common Stock, Par Value | $ / shares		$ .001			$ 0.001	$ .001	$ 0.001	$ 0.001
Common Stock, Shares Authorized | shares		2,000,000,000			375,030,000	2,000,000,000	375,030,000	900,000
Stock split ratio		0.05		0.01	4.1671
Accrued expenses		$ 1,077,101				$ 937,783
Default Penalty to be recognized	$ 65,958
Consulting Agmt
Date of Agreement		Jul. 7, 2017
Term of Agreement		2 years
Annual Compensation		$ 180,000
Collaboration Agmt
Date of Agreement		Jul. 11, 2017
Account Receivable		$ 100,000
Common Stock, Receivable | shares		15,000,000
Debt Conversion #144
Date of Issuance		Jul. 3, 2017
Debt Instrument, Converted Amount		$ 2,088
Common Stock, shares issued | shares		17,400,000
Common Stock, price per share | $ / shares		$ 0.00012
Debt Conversion #145
Date of Issuance		Jul. 12, 2017
Debt Instrument, Converted Amount		$ 2,088
Common Stock, shares issued | shares		17,400,000
Common Stock, price per share | $ / shares		$ 0.00012
Debt Conversion #146
Date of Issuance		Jul. 13, 2017
Debt Instrument, Converted Amount		$ 2,484
Common Stock, shares issued | shares		13,800,000
Common Stock, price per share | $ / shares		$ 0.00018
Debt Conversion #147
Date of Issuance		Jul. 14, 2017
Debt Instrument, Converted Amount		$ 3,374
Common Stock, shares issued | shares		19,000,000
Common Stock, price per share | $ / shares		$ 0.00018
Debt Conversion #148
Date of Issuance		Jul. 3, 2017
Debt Instrument, Converted Amount		$ 3,374
Common Stock, shares issued | shares		19,000,000
Common Stock, price per share | $ / shares		$ 0.00018
Debt Conversion #149
Date of Issuance		Jul. 20, 2017
Debt Instrument, Converted Amount		$ 3,582
Common Stock, shares issued | shares		19,900,000
Common Stock, price per share | $ / shares		$ 0.00018
Debt Conversion #150
Date of Issuance		Jul. 24, 2017
Debt Instrument, Converted Amount		$ 6,270
Common Stock, shares issued | shares		20,900,000
Common Stock, price per share | $ / shares		$ 0.00018
Debt Conversion #151
Date of Issuance		Jul. 25, 2017
Debt Instrument, Converted Amount		$ 6,870
Common Stock, shares issued | shares		22,900,000
Common Stock, price per share | $ / shares		$ 0.0003
Debt Conversion #152
Date of Issuance		Jul. 28, 2017
Debt Instrument, Converted Amount		$ 7,200
Common Stock, shares issued | shares		24,000,000
Common Stock, price per share | $ / shares		$ 0.0003
Debt Conversion #153
Date of Issuance		Aug. 2, 2017
Debt Instrument, Converted Amount		$ 7,200
Common Stock, shares issued | shares		24,000,000
Common Stock, price per share | $ / shares		$ 0.0003
Debt Conversion #154
Date of Issuance		Aug. 4, 2017
Debt Instrument, Converted Amount		$ 9,000
Common Stock, shares issued | shares		25,000,000
Common Stock, price per share | $ / shares		$ 0.00036
Debt Conversion #155
Date of Issuance		Aug. 8, 2017
Debt Instrument, Converted Amount		$ 11,119
Common Stock, shares issued | shares		26,475,000
Common Stock, price per share | $ / shares		$ 0.00042
Debt Conversion #156
Date of Issuance		Aug. 11, 2017
Debt Instrument, Converted Amount		$ 13,920
Common Stock, shares issued | shares		29,000,000
Common Stock, price per share | $ / shares		$ 0.00048
Debt Conversion #157
Date of Issuance		Aug. 16, 2017
Debt Instrument, Converted Amount		$ 12,810
Common Stock, shares issued | shares		30,500,000
Common Stock, price per share | $ / shares		$ 0.00042
Debt Conversion #158
Date of Issuance		Aug. 22, 2017
Debt Instrument, Converted Amount		$ 6,709
Common Stock, shares issued | shares		19,168,058
Common Stock, price per share | $ / shares		$ 0.00035
Debt Conversion #159
Date of Issuance		Aug. 25, 2017
Debt Instrument, Converted Amount		$ 11,200
Common Stock, shares issued | shares		32,000,000
Common Stock, price per share | $ / shares		$ 0.00035
Debt Conversion #160
Date of Issuance		Aug. 31, 2017
Debt Instrument, Converted Amount		$ 9,600
Common Stock, shares issued | shares		32,000,000
Common Stock, price per share | $ / shares		$ 0.0003
Debt Conversion #161
Date of Issuance		Sep. 7, 2017
Debt Instrument, Converted Amount		$ 9,900
Common Stock, shares issued | shares		36,000,000
Common Stock, price per share | $ / shares		$ 0.00028
Debt Conversion #162
Date of Issuance		Sep. 15, 2017
Debt Instrument, Converted Amount		$ 9,437
Common Stock, shares issued | shares		37,900,000
Common Stock, price per share | $ / shares		$ 0.00025
Debt Conversion #163
Date of Issuance		Sep. 22, 2017
Debt Instrument, Converted Amount		$ 9,910
Common Stock, shares issued | shares		39,800,000
Common Stock, price per share | $ / shares		$ 0.00025
Debt Conversion #164
Date of Issuance		Sep. 28, 2017
Debt Instrument, Converted Amount		$ 10,408
Common Stock, shares issued | shares		41,800,000
Common Stock, price per share | $ / shares		$ 0.00025
Debt Conversion #165
Date of Issuance		Oct. 3, 2017
Debt Instrument, Converted Amount		$ 10,931
Common Stock, shares issued | shares		43,900,000
Common Stock, price per share | $ / shares		$ 0.00025
Debt Conversion #166
Date of Issuance		Oct. 5, 2017
Debt Instrument, Converted Amount		$ 7,582
Common Stock, shares issued | shares		30,448,193
Common Stock, price per share | $ / shares		$ 0.00025